What's Happening?
Anixa Biosciences, a biotechnology company focused on cancer treatment and prevention, has reported encouraging survival data from its ongoing Phase 1 clinical trial of liraltagene autoleucel (lira-cel), a CAR-T therapy targeting the follicle-stimulating
hormone receptor (FSHR) for recurrent ovarian cancer. The trial, conducted in collaboration with Moffitt Cancer Center, has shown that several patients have survived significantly beyond the expected median survival of three to four months. Notably, one patient survived 28 months post-treatment, while others have survived between seven and 18 months. The trial's preliminary safety data indicate no dose-limiting toxicities or significant adverse events related to the therapy. The findings were presented at the International Society for Cell & Gene Therapy 2026 Annual Meeting.
Why It's Important?
The positive survival outcomes from Anixa's trial are significant as they offer hope for patients with recurrent ovarian cancer, a condition with limited treatment options and poor prognosis. The use of CAR-T therapy, particularly targeting FSHR, represents a novel approach in oncology, potentially improving survival rates and quality of life for patients. The trial's success could pave the way for further development and eventual approval of lira-cel, impacting the broader field of cancer immunotherapy. This development underscores the potential of CAR-T therapies to address challenging cancers and highlights the importance of continued innovation in cancer treatment.
What's Next?
Anixa plans to continue the trial with dose escalation, aiming to evaluate a higher dose of lira-cel combined with lymphodepletion using cyclophosphamide and fludarabine. This approach is expected to enhance CAR-T cell expansion and activity. The company will monitor patient outcomes closely and assess the therapy's long-term efficacy and safety. The results of these efforts could influence future regulatory decisions and the potential commercialization of lira-cel, impacting treatment protocols for ovarian cancer.
